Astrazeneca Plc $AZN Shares Acquired by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. increased its stake in Astrazeneca Plc (NYSE:AZN) by 5.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,328 shares of the company’s stock after purchasing an additional 2,819 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Astrazeneca were worth $9,886,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Bangor Savings Bank lifted its holdings in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Eagle Bay Advisors LLC acquired a new stake in Astrazeneca in the fourth quarter worth about $30,000. Triumph Capital Management acquired a new stake in Astrazeneca in the third quarter worth about $25,000. YANKCOM Partnership acquired a new stake in Astrazeneca in the fourth quarter worth about $31,000. Finally, TFC Financial Management Inc. lifted its holdings in Astrazeneca by 3,350.0% in the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after purchasing an additional 335 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on AZN shares. Barclays raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Thursday, April 30th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Astrazeneca has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Trading Up 0.4%

NYSE:AZN opened at $184.69 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The stock’s 50-day moving average is $191.97 and its two-hundred day moving average is $182.43. The stock has a market cap of $286.44 billion, a PE ratio of 27.73, a price-to-earnings-growth ratio of 1.51 and a beta of 0.26.

Astrazeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. As a group, equities research analysts forecast that Astrazeneca Plc will post 10.25 earnings per share for the current fiscal year.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca and Daiichi Sankyo won FDA approval for Enhertu in two additional early-stage HER2-positive breast cancer settings, expanding the drug’s addressable market and strengthening the company’s oncology pipeline. AZN, Daiichi’s Enhertu Gets FDA Nod for Two New Breast Cancer Settings
• Positive Sentiment: The FDA also approved Baxfendy (baxdrostat), AstraZeneca’s first-in-class hypertension drug, which could become a meaningful new growth driver in a large cardiovascular market and may support expectations for multibillion-dollar peak sales. AstraZeneca’s blood pressure drug wins U.S. approval
• Neutral Sentiment: Some commentary on the FDA wins raised questions about valuation and the pace of long-term growth, suggesting investors may balance the near-term enthusiasm against execution and pricing concerns. AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation
• Neutral Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for AstraZeneca to $10.17 from $10.25, though that remains close to the consensus of $10.26 and does not materially change the earnings outlook.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.